---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-010348"
form_type: "8-K"
ticker: "CLDI"
cik: "0001855485"
company_name: "Calidi Biotherapeutics, Inc."
filed_at: "2025-05-14T23:59:59+00:00"
generated_at: "2026-05-21T10:26:20.758891+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Calidi reports Q1 net loss $5.0M; CEO transition to Eric Poma; FDA clears CLD-201 IND

## Summary
- CEO transition: Eric Poma appointed CEO; 30+ yrs biopharma; raised >$250M at Molecular Templates.
- FDA cleared IND for CLD-201 (allogeneic stem cell therapy) for solid tumors; CIRM non-dilutive funding.
- Selected IL-15 superagonist as first payload for Redtail platform; IND filing expected H2 2026.
- Q1 net loss $5.0M ($0.18/share) vs $7.2M ($2.03/share) in Q1 2024; R&D $2.4M, G&A $2.6M.
- Cash $10.6M at March 31, 2025, up from $9.6M at Dec 31, 2024.

## SEC filing metadata
- accession: 0001641172-25-010348
- form_type: 8-K
- ticker: CLDI
- cik: 0001855485
- company_name: Calidi Biotherapeutics, Inc.
- filed_at: 2025-05-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855485/000164117225010348/0001641172-25-010348-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855485/000164117225010348/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-010348
- JSON: https://secwatch.observer/filing/0001641172-25-010348.json
- Plain text: https://secwatch.observer/filing/0001641172-25-010348.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.